



To,
BSE Limited
P. J. Towers,
Dalal Street,
Mumbai – 400001

Date: 30.05.2025

Dear Sir/ Madam,

Unit: Decipher Labs Limited (Scrip Code: 524752)

Sub: Outcome of Board Meeting for the quarter and year ended 31.03.2025 under regulation 30 and 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.

With reference to the subject cited, this is to inform the Exchange that the Board of Directors of **Decipher Labs Limited** at its meeting held on Friday, the 30th day of May, 2025 at 05:30 p.m. at registered office of the Company for the quarter and financial year ended 31.03.2025 considered and approved the following:

1. Audited Financial Results (standalone and consolidated) for the quarter and financial year ended 31.03.2025. (**Attached**)
2. Auditors Report (standalone and consolidated) along with declaration of unmodified opinion for the financial year ended 31.03.2025. (**Attached**)
3. Appointment of Mrs. Ankita Mathur (DIN - 05329604) as additional Director (Executive category) of the Company for a period of three years w.e.f. 30.05.2025. (**Details are Attached as Annexure A**)
4. Change in designation of Mr. Sushant Mohan Lal (DIN- 01227151) from Executive Director to Non-Executive Director of the Company w.e.f. 30.05.2025 (post-closing hours). (**Details are Attached as Annexure A**)

The meeting concluded at 7:20 P.M.

This is for the information and records of the Exchange, please.

Thanking you.

Yours Faithfully
For Decipher Labs Limited

Sushant Mohan Lal
Executive Director
(DIN: 01227151)



To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400001

Date: 30-May-2025

Dear Sir,

Unit: Decipher Labs Limited (Scrip Code: 524752)

Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for Unmodified Opinion.

I, **Sushant Mohan Lal**, Executive Director of **Decipher Labs Limited** hereby declare that, the Statutory Auditors of the company, M/s. Ramanathan & Rao have issued an Audit Report with unmodified/unqualified opinion on Standalone and Consolidated Audited Financial Results of the company for the quarter and year ended 31st March, 2025.

This declaration is issued in compliance of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you.

Yours faithfully,
For Decipher Labs Limited

Sushant Mohan Lal
Executive Director
(DIN: 01227151)



Annexure - A

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024]

S. No	Particulars	Mrs. Ankita Mathur	Mr. Sushant Mohan Lal
1.	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of Mrs. Ankita Mathur as additional Director (Executive category) of Decipher Labs Limited.	Change in designation of Mr. Sushant Mohan Lal from Executive Director to Non-Executive Director
2.	Date of appointment & Terms of appointment	w.e.f .30.05.2025 Terms of Appointment: Appointed for a period of three years w.e.f. 30.05.2025 at a remuneration of Rs. 1,00,000/- per month subject to approval of shareholder.	w.e.f 30.05.2025 (post-closing hours) Terms of Appointment: Change in designation of Mr. Sushant Mohan Lal from Executive Director to Non- Executive Director
3.	Brief Profile	Dr. Ankita Mathur is a highly accomplished professional in the audiology field. Her expertise in providing evaluation and intervention for speech and hearing disorders as well as dispensing various brands of hearing aids makes her a valuable resource for anyone experiencing hearing issues. Her involvement with NGOs and social services adds a compassionate dimension to her work, focusing not only on direct patient care but also on empowerment through education for parents, special educators, and even acting as a part-time teaching faculty.	He is MBA from Kansas University, USA. He has been associated with the Company since long.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Except Mr. Sushant Mohan Lal (DIN: 01227151) Non-Executive Director being his relative, none of the other Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, financially	Except Mrs. Ankita Mathur (DIN: 05329604) Executive Director his relative, none of the other Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested,



DECIPHER LABS LIMITED

Formerly Combat Drugs Limited

Regd.Off: A-2, Q2, 5th Floor, Cyber Towers, Hitech City, Madhapur, Hyderabad, Shaikpet, Telangana, India, 500081

Ph: (+91)-40-48536100 Url: www.decipherlabs.in Mail: decipherlabsltd@gmail.com

D.L.No. TG/15/04/2016-14766/14767 CINNo.L24230TG1986PLC006781 GST:36AAACC8372L1ZB

		or otherwise.	financially or otherwise.
5.	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Ltd with ref. no NSE/CML/2018/24 dated June 20, 2018	Mrs. Ankita Mathur is not debarred from holding office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such statutory authority.	Mr. Sushant Mohan Lal is not debarred from holding office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such statutory authority.

To,

Date: 30.05.2025

The Board of Directors,

Decipher Labs Limited,

A-2, Q2, 5th Floor, Cyber Towers,
Hitech City, Madhapur, Hyderabad,
Telangana, India, 500081.


Sub: Resignation as Executive Director and continue as Non- Executive Director.

I hereby tender my resignation as Executive Director of the Company with effect from 30.05.2025 (Post Closing Hours) to focus on other commitments. However, I remain deeply committed to the mission and long-term success of the organization. To that end, I would be pleased to continue contributing as a Non-Executive Director on the Board, subject to the board's approval.

Thank you for the opportunity to serve as Executive Director. I look forward to continuing to support the organization in a strategic and advisory capacity.

Thanking you

Yours faithfully




Sushant Mohan Lal

DECIPHER LABS LIMITED (CIN CL23230TG1986PLC006781) Regd.off: A-2, Q2, 5th Floor, Cyber Towers Madhapur, Hyderabad, Telangana, India - 500081 URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-29323151 Standalone statement of Assets and Liabilities as on 31 March 2025		
	Rs. in Lakhs	
Particulars	As at 31st March 2025	As at 31st March 2024
	Audited	Audited
I. ASSETS		
Non-current assets		
(a) Property Plant and Equipment	13.80	10.43
(b) Financial assets		
Investments	866.41	866.41
(c) Other non-current assets	3.50	0.30
(d) Deferred Tax Assets	1.68	1.81
Current assets		
(a) Financial assets		
(i) Trade receivables	22.68	394.50
(ii) Cash and cash equivalents	5.47	2.65
(b) Current tax assets	0.21	-
(c) Other current assets	4.08	-
TOTAL ASSETS	917.82	1,276.10
II. EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	1,010.00	1,010.00
(b) Other equity	(161.27)	(117.24)
Liabilities		
Current Liabilities		
(a) Financial liabilities		
(i) Borrowings	24.45	-
(ii) Trade payables		
a) Total outstanding dues of Micro and small enterprises	-	-
b) Total outstanding dues of creditors other than Micro and small enterprises	23.78	369.64
(iii) Other financial liabilities	20.05	13.23
(b) Other current liabilities	0.81	0.48
TOTAL EQUITY AND LIABILITIES	917.82	1,276.10

Place: Hyderabad
Date: 30.05.2025

For and on behalf of the Board



Sushant Mohan Lal
Executive whole time director
DIN: 01227151



DECIPHER LABS LIMITED

(CIN C123230TG1986PLC006781)

Regd. off: A-2, Q2, 5th Floor, Cyber Towers
Madhapur, Hyderabad, Telangana, India - 500081

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-29323151

Statement of Audited Standalone Financial Results For the Quarter and Year Ended 31st March, 2025

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Year ended	
	31.03.2025	31.12.2024	31.03.2024	31.03.2025	31.03.2024
	Audited	Unaudited	Audited	Audited	Audited
I. Revenue from operations	22.60	16.00	335.67	85.32	353.16
II. Other income	0.01	0.33	0.50	2.28	1.99
III. Total Income (I + II)	22.61	16.33	336.17	87.60	355.15
IV. Expenses					
Purchase of Stock in trade	23.00	15.00	313.77	67.25	313.77
Changes in inventories of stock in trade	-	-	-	-	-
Employee Benefits Expense	8.30	3.01	4.25	23.43	16.99
Finance Costs	-	-	-	-	-
Depreciation expense	0.45	0.45	0.35	1.67	1.45
Other expenses	7.30	6.96	5.04	39.14	20.42
Total expenses	39.05	25.43	323.41	131.49	352.63
V. Profit/(Loss) before Exceptional items (III - IV)	(16.45)	(9.09)	12.75	(43.90)	2.52
VI. Exceptional items	-	-	-	-	-
VII. Profit/(Loss) after Exceptional items (V - VI)	(16.45)	(9.09)	12.75	(43.90)	2.52
VIII. Tax expense:					
(1) Current tax	-	-	-	-	-
(2) Deferred tax	(0.37)	(0.12)	(0.34)	(0.13)	(0.18)
IX. Profit/(Loss) for the period (VII-VIII)	(16.81)	(9.21)	12.41	(44.02)	2.34
X. Other comprehensive income	-	-	-	-	-
XI. Total comprehensive income for the year	(16.81)	(9.21)	12.41	(44.02)	2.34
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00
XII. Earning per equity share					
(1) Basic	(0.17)	(0.09)	0.12	(0.44)	0.02
(2) Diluted	(0.17)	(0.09)	0.12	(0.44)	0.02
Notes					
1. The operations of the Company relate to two segments viz., Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.					
Segment Information:					
Particulars	Quarter ended			Year Ended	
	31.03.2025	31.12.2024	31.03.2024	31.03.2025	31.03.2024
	Audited	Unaudited	Audited	Audited	Audited
Segment Revenue					
a) Manufacturing and Trading of Pharmaceutical drugs	22.60	16.00	327.33	68.60	327.33
b) Consultancy Services	0.00	-	8.34	16.72	25.83
Total Sales	22.60	16.00	335.67	85.32	353.16
Less: Inter Segment Revenue	-	-	-	-	-
Total Revenue from Operations	22.60	16.00	335.67	85.32	353.16
Segment Result (Profit Before Tax and Interest from each Segment)					
a) Manufacturing and Trading of Pharmaceutical drugs	(15.16)	(8.34)	21.89	(35.29)	2.33
b) Consultancy Services	(1.28)	(0.75)	(9.15)	(8.60)	0.18
Total	(16.45)	(9.09)	12.74	(43.90)	2.52
Less: Interest and exceptional items	-	-	-	-	-
Total Profit before tax	(16.45)	(9.09)	12.74	(43.90)	2.52
Capital employed (Segment assets - segment liabilities)					
Segment assets					
a) Manufacturing and trading of Pharmaceutical drugs	913.55	910.76	1,267.85	913.55	1,267.85
b) Consultancy Services	4.27	17.12	8.25	4.27	8.25
Total Assets	917.82	927.88	1,276.10	917.82	1,276.10
Segment liabilities					
a) Manufacturing and trading of Pharmaceutical drugs	69.09	62.81	383.34	69.09	383.34
b) Consultancy Services	-	-	-	-	-
c) Unallocated liabilities	-	-	-	-	-
Total Liabilities	69.09	62.81	383.34	69.09	383.34
2. The above results for the quarter and year ended 31st March 2025 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 30th May 2025.					
3. The financial results of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure					

For and on behalf of the Board



Sushant Mohan Lal
Executive Director
DIN: 01227151



Place: Hyderabad
Date: 30.05.2025

DECIPHER LABS LIMITED (CIN CL23230TG1986PLC006781) Regd.off: A-2, Q2, 5th Floor, Cyber Towers Madhapur, Hyderabad, Telangana, India - 500081 URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-29323151 Standalone Statement of Cash Flows for the Year Ended 31st March 2025 All amounts in ₹ Lakhs, unless otherwise stated			
Particulars	Year ended 31st March, 2025 (Audited)		Year ended 31st March, 2024 (Audited)
A. CASH FLOW FROM OPERATING ACTIVITIES			
Profit before tax		(43.90)	2.51
Adjustments for :			
Depreciation		1.67	1.45
Loss on sale of asset		(0.37)	-
Operating Profit before Working Capital Changes		(42.60)	3.96
Adjustments for:			
(Increase) / Decrease in Trade Receivables	371.82		(381.75)
(Increase) / Decrease in Inventories	-		-
(Increase) / Decrease in Other Assets	(4.29)		0.03
(Increase) / Decrease in Other Non Current Assets	(3.20)		-
Increase / (Decrease) in Trade Payable	(345.86)		369.64
Increase / (Decrease) in Other Liabilities	31.61		5.16
		50.08	(6.93)
Cash Generated from Operations		7.48	(2.97)
Direct Taxes Paid		-	-
Net Cash generated from/(used in) Operating Activities		7.48	(2.97)
B. CASH FLOW FROM INVESTING ACTIVITIES			
Sale of Fixed Asset	1.02		-
Purchase of Fixed Asset	(5.69)		-
Net Cash used in Investing Activities		(4.67)	-
C. CASH FLOW FROM FINANCING ACTIVITIES			
Net increase/(decrease) in Cash and Cash Equivalents		2.81	(2.97)
Cash and Cash Equivalents at the beginning of the year		2.65	5.62
Cash and Cash Equivalents at the end of the period		5.48	2.65

For and on behalf of the Board



Sushant Mohan Lal
Executive Director
DIN: 01227151



Place: Hyderabad
Date: 30.05.2025

Decipher Labs Limited (CIN CL23230TG1986PLC006781) Regd.off: A-2, Q2, 5th Floor, Cyber Towers Madhapur, Hyderabad, Telangana, India - 500081 URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-29323151 Consolidated Statement of Assets and Liabilities as at 31st March 2025 All amounts in ₹ Lakhs, unless otherwise stated		
Particulars	As at 31st March, 2025 (Audited)	As at 31st March, 2024 (Audited)
I. ASSETS		
Non-current Assets		
(a) Property, Plant and Equipment	82.83	88.00
(b) Investment	26.41	338.93
(c) Deferred tax asset (net)	187.52	55.64
(d) Goodwill	171.19	202.63
(e) Other non current assets	3.50	210.31
Current Assets		
(a) Financial assets		
(i) Trade receivables	421.63	779.84
(ii) Cash and cash equivalents	280.84	931.38
(iii) Other Financial Asset	201.64	96.51
(b) Other current assets	1,200.91	660.08
TOTAL ASSETS	2,576.48	3,363.31
II. EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	1,010.00	1,010.00
(b) Other equity	1,275.57	1,176.06
Liabilities		
Current Liabilities		
(a) Financial liabilities		
(i) Borrowings	24.45	-
(ii) Trade payables		
a) Total outstanding dues of Micro enterprises and small enterprises	-	-
b) Total outstanding dues of creditors other than Micro enterprises and small enterprises	115.67	499.38
(iii) Other Financial liabilities	149.98	677.41
(b) Other current liabilities	0.81	0.46
TOTAL EQUITY AND LIABILITIES	2,576.48	3,363.31

For and on behalf of the Board



Sushant Mohan Lal
Executive whole time director
DIN: 01227151

Place: Hyderabad
Date: 30.05.2025



Decipher Labs Limited
(CIN CL23230TG1986PLC006781)

Regd.off: A-2, Q2, 5th Floor, Cyber Towers
Madhapur, Hyderabad, Telangana, India - 500081

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-29323151

Statement of Audited Consolidated Financial Results For the Quarter and Year Ended March 31, 2025

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter Ended			Year Ended	
	31.03.2025	31.12.2024	31.03.2024	31.03.2025	31st March, 2024
	Audited	Unaudited	Audited	Audited	Audited
I. Revenue from operations	350.01	580.47	1,059.13	2,261.25	3,587.85
II. Other income	87.05	16.87	27.10	131.82	41.65
III. Total revenue (I + II)	437.06	597.34	1,086.23	2,393.07	3,629.51
IV. Expenses					
Purchase of Stock-in-Trade	23.00	15.00	313.77	67.25	313.77
Employee benefits expense	376.27	582.82	540.22	2,139.16	2,774.94
Finance costs	-	-	21.24	-	21.76
Depreciation and amortisation expense	12.65	12.20	11.15	47.63	45.27
Other expenses	608.34	45.79	83.58	777.65	594.87
Total expenses	1,020.26	655.81	969.96	3,031.69	3,750.61
V. Profit/(Loss) before Exceptional item (III - IV)	(583.20)	(58.47)	116.27	(638.62)	(121.11)
VI. Exceptional items	-	-	-	-	-
VII. Profit/(Loss) before tax (III - IV)	(583.20)	(58.47)	116.27	(638.62)	(121.11)
VIII. Tax expense:					
(1) Current tax	-	-	-	-	-
(2) Deferred tax	(172.59)	0.80	(4.22)	(130.60)	46.45
IX. Profit/(Loss) for the period (V-VI)	(410.61)	(59.27)	120.49	(508.02)	(167.55)
X. Other comprehensive income					
Items that will be reclassified to statement of profit and loss	-	-	-	-	-
Exchange differences on translating the financial statements of foreign Subsidiaries	2.24	22.12	4.75	52.38	32.77
XI. Total comprehensive income for the year	(408.37)	(37.16)	125.24	(455.64)	(134.78)
Net Profit/(Loss) for the year attributable to:					
Owners of the parent	(410.61)	(59.27)	120.49	(508.02)	(167.55)
Non-Controlling Interests	-	-	-	-	-
Other Comprehensive Income attributable to:					
Owners of the parent	99.65	(37.16)	4.75	52.38	32.77
Non-Controlling Interests	-	-	-	-	-
Total Comprehensive Income attributable to:					
Owners of the parent	(408.37)	(37.16)	125.24	(455.64)	(134.78)
Non-Controlling Interests	-	-	-	-	-
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00
XI. Earning per equity share					
(1) Basic	(4.07)	(0.59)	1.19	(5.03)	(1.66)
(2) Diluted	(4.07)	(0.59)	1.19	(5.03)	(1.66)

Notes

1. The operations of the Group relate to two segments viz.; Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter Ended			Year Ended	
	31.03.2025	31.12.2024	31.03.2024	31.03.2025	31st March, 2024
	Audited	Unaudited	Audited	Audited	Audited
Segment Revenue					
a) Manufacturing and Trading of Pharmaceutical drugs	22.60	16.00	327.33	68.60	327.33
b) Consultancy Services	327.41	564.47	731.79	2,192.65	3,260.52
Total Sales	350.01	580.47	1,059.12	2,261.25	3,587.85
Less: Inter Segment Revenue	-	-	-	-	-
Total Revenue from Operations	350.01	580.47	1,059.12	2,261.25	3,587.85
Segment Result (Profit Before Tax and Interest from each Segment)					
a) Manufacturing and Trading of Pharmaceutical drugs	0.76	(8.34)	1.17	(19.37)	(9.06)
b) Consultancy Services	(583.95)	(50.21)	136.33	(619.24)	(90.28)
Total	(583.20)	(58.55)	137.51	(638.62)	(99.35)
Less: Interest and exceptional item	-	-	21.24	(130.60)	21.76


Total Profit/(Loss) before tax	(583.20)	(58.55)	116.27	(508.02)	(121.11)
Capital employed (Segment assets - segment liabilities)					
Segment assets					
a) Manufacturing and trading of Pharmaceutical drugs	913.55	910.76	427.85	913.55	427.85
b) Consultancy Services	1,662.93	2,172.16	2,935.46	1,662.93	2,935.46
Total Assets	2,576.48	3,082.91	3,363.31	2,576.48	3,363.31
Segment liabilities					
a) Manufacturing and trading of Pharmaceutical drugs	69.09	62.81	383.34	69.09	383.34
b) Consultancy Services	221.82	881.32	793.91	221.82	793.91
Total Liabilities	290.91	944.13	1,177.25	290.91	1,177.25

2. The above results for the quarter and year ended 31st March 2025 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 30th May 2025.

3. The financial results of the Group have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

4. The above results as of 31 March 2025 include results of wholly owned subsidiary Decipher Software Solutions LLC, USA and step down subsidiary Decipher W.L.L., Bahrain.

For and on behalf of the Board



Sushant Mohan Lal
Executive Director
DIN: 01227151



Place: Hyderabad

Date: 30.05.2025

Decipher Labs Limited

(CIN CL23230TG1986PLC006781)

Regd.off: A-2, Q2, 5th Floor, Cyber Towers

Madhapur, Hyderabad, Telangana, India - 500081

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-29323151

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31ST MARCH, 2025

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Year Ended 31st March, 2025 (Audited)	Year Ended 31st March, 2024 (Audited)
Cash flow from operating activities		
Profit/(Loss) before tax	(638.62)	(121.11)
Adjustments for :		
Exchange differences on translating the financial statements of a foreign operation	52.38	32.77
Depreciation and amortisation expense	36.61	45.27
Finance costs	-	21.76
Baddebts written off	28.54	-
ERC Credit	555.14	-
Operating Profit before Working Capital Changes		
Changes in operating assets and liabilities		
(Increase) / Decrease in Trade Receivables	329.67	205.59
(Increase) / Decrease in Other Assets	(439.16)	(475.45)
Increase / (Decrease) in Trade Payable	(383.71)	379.24
Increase / (Decrease) in Other Liabilities	(522.68)	397.35
Cash Generated from Operations	(981.82)	485.42
Income taxes paid	-	-
Net cash inflow (outflow) from operating activities	(981.82)	485.42
Cash flows from investing activities		
Purchase of Fixed assets including Capital WIP	(5.69)	(5.84)
Impairment of investment/sale of investment	312.52	(173.26)
Net cash inflow (outflow) from investing activities	306.83	(179.10)
Cash flow from financing activities		
Proceeds/(repayment) of borrowings	24.45	(94.94)
Finance costs	-	(21.76)
Net cash inflow (outflow) from financing activities	24.45	(116.70)
Net increase (Decrease) in cash and cash equivalents	(650.54)	189.61
Cash and Cash equivalents at the beginning of the Year	931.38	741.77
Cash and Cash equivalents at the end of the Year	280.84	931.38

For and on behalf of the Board



Sushant Mohan Lal
Executive Director
DIN: 01227151



Place: Hyderabad
Date: 30.05.2025



**Independent Auditor's Report on the Quarterly and Year to Date Audited Standalone Financial Results
of Decipher Labs Limited Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015**

To
The Board of Directors of Decipher Labs Limited

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone quarterly financial results of Decipher Labs Limited (Formerly known as Combat Drugs Limited) (the Company) for the quarter ended 31st March, 2025 and the year-to-date results for the period from 1st April, 2024 to 31st March, 2025, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("LODR Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net loss and other comprehensive income and other financial information for the quarter ended 31st March, 2025 as well as the year-to-date results for the period from 1st April, 2024 to 31st March, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the standalone Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.



Management's Responsibilities for the Standalone Financial Results

These quarterly standalone financial results as well as the year-to-date financial results have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.



Ramanatham & Rao

Chartered Accountants

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone financial results made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.



Ramanatham & Rao

Chartered Accountants


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The standalone financial results include the results for the quarter ended 31st March, 2025 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.S-2934)



K.Sreenivasan
Partner
Membership No.206421

UDIN: 25206421BMIWDW7172

Place : Secunderabad
Date : 30.05.2025





Independent Auditor's Report on the Quarterly and Year to Date Audited Consolidated Financial Results of Decipher Labs Limited Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors of Decipher Labs Limited
Report on the Audit of Consolidated Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of Decipher Labs Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the Quarter and year ended 31st March, 2025, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('LODR Regulations').

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial statements/financial results/financial information of the subsidiaries, the aforesaid consolidated financial results:

- i. include the annual financial results of the following entities
Decipher Software Solutions LLC, USA, Subsidiary - Direct
Decipher Soft Middle East W.L.L Bahrain, Subsidiary - Indirect
- ii. are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- iii. give a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of net loss and other comprehensive income and other financial information of the Group for the year ended 31st March, 2025.



Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditor in terms of their report referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated financial results.

Board of Directors' Responsibilities for the Consolidated Financial Results

These Consolidated financial results have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.



Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the holding company and subsidiary company incorporated in India have adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.



- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the consolidated financial results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated financial results, which have been audited by other auditor, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by SEBI under Regulation 33(8) of the LODR Regulations, as amended, to the extent applicable.

Other Matters

1. The consolidated financial results include the financial results of Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain whose financial statements/financial results/ financial information reflect total assets of Rs 2499.55 Lakhs as at 31st March, 2025, total revenue of Rs 414.45 lakhs and Rs 2305.47 lakhs, total net profit/(loss) of Rs (393.80) lakhs and Rs (464.00) lakhs for the quarter ended 31st March, 2025 and for the period from 1st April, 2024 to 31st March, 2025 respectively, and net cash inflow of Rs (647.73) lakhs for the year ended 31st March, 2025. The independent auditors' reports on financial statements/financial results/ financial information of these entities has been furnished to us and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the reports of such auditors and the procedures performed by us are as stated in the paragraph above.



Ramanatham & Rao


Chartered Accountants

Our opinion on the consolidated financial results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial results/financial information certified by the Board of Directors.

The financial statements of subsidiaries, located outside India, have been prepared in accordance with accounting principles generally accepted in that country and which have been audited by other auditors under generally accepted auditing standards applicable in that country. The Management has converted the financial statements of the subsidiaries located outside India from accounting principles generally accepted in that country to accounting principles generally accepted in India. We have audited these conversion adjustments made by the Management. Our opinion in so far as it relates to the balances and affairs of such subsidiaries is based on the report of other auditors and the conversion adjustments prepared by the Management and audited by us. Our opinion is not modified in respect of this matter.

2. The consolidated Financial Results include the results for the quarter ended 31st March, 2025 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.S-2934)



K.Sreenivasan

Partner

Membership No.206421

UDIN: 25206421BMIWDY2823

Place : Secunderabad

Date :30.05.2025

